PMID- 17988434
OWN - NLM
STAT- MEDLINE
DCOM- 20080222
LR  - 20181201
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 23
IP  - 12
DP  - 2007 Dec
TI  - Effectiveness of open-label donepezil treatment in patients with Alzheimer's 
      disease discontinuing memantine monotherapy.
PG  - 3153-65
AB  - OBJECTIVE: To evaluate the efficacy and safety of donepezil in patients with 
      Alzheimer's disease (AD) who discontinue memantine due to a lack of efficacy or 
      not being well tolerated. METHODS: This study enrolled patients with 
      moderate-to-severe AD (Mini-Mental State Examination [MMSE] score 5-17) who had a 
      history of treatment with memantine monotherapy (10 mg/BID) for > or = 3 months 
      prior to screening and maintained until study baseline. For inclusion in this 
      study, the patient's memantine treatment had to have been judged as lacking 
      efficacy or not well tolerated at the screening visit. Information on previous 
      memantine use was also obtained with regard to dose and duration of treatment. At 
      the baseline visit, patients were switched to open-label donepezil 5 mg/day for 4 
      weeks, and 10 mg/day thereafter. The primary efficacy measure was a change in 
      MMSE at week 12 using a last observation carried forward (LOCF) analysis. 
      Secondary measures included Physician and Caregiver Satisfaction Questionnaires 
      (PSQ, CSQ), the Clinical Global Impression-Improvement (CGI-I), Neuropsychiatric 
      Inventory (NPI), and a Caregiver Diary (CD). RESULTS: At week 12-LOCF, MMSE 
      scores increased by a mean of 1.55 points from baseline (p < 0.0001). At end 
      point, the PSQ and CSQ indicated consistent improvements in satisfaction/ease of 
      use with donepezil; 60.2% of patients improved on the CGI-I; and 44.4-55.6% 
      improved on each of three components of the CD. Improvements on the MMSE, CSQ, 
      and CGI-I were apparent, irrespective of previous cholinesterase (ChE) inhibitor 
      use. No significant effects were seen for the total score on the NPI. Withdrawal 
      rates (8.7% due to adverse events [AEs]) and AEs were consistent with the known 
      donepezil safety profile. CONCLUSION: Donepezil was effective and well tolerated 
      in moderate-to-severe AD patients who discontinued memantine monotherapy, 
      including those with previous exposure to ChE inhibitors.
FAU - Sakka, Paraskevi
AU  - Sakka P
AD  - HYGEIA Diagnostic & Therapeutic Center of Athens, Athens, Greece. 
      vsakka@ath.forthnet.gr
FAU - Tsolaki, Magda
AU  - Tsolaki M
FAU - Hort, Jakub
AU  - Hort J
FAU - Hager, Klaus
AU  - Hager K
FAU - Soininen, Hilkka
AU  - Soininen H
FAU - Lopez Pousa, Secundino
AU  - Lopez Pousa S
FAU - Li, Chunming
AU  - Li C
FAU - Schwam, Elias
AU  - Schwam E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Indans)
RN  - 0 (Piperidines)
RN  - 8SSC91326P (Donepezil)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy
MH  - Antiparkinson Agents/adverse effects/*therapeutic use
MH  - Cholinesterase Inhibitors/adverse effects/*therapeutic use
MH  - Donepezil
MH  - Female
MH  - Humans
MH  - Indans/adverse effects/*therapeutic use
MH  - Male
MH  - Memantine/therapeutic use
MH  - Middle Aged
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2007/11/09 09:00
MHDA- 2008/02/23 09:00
CRDT- 2007/11/09 09:00
PHST- 2007/11/09 09:00 [pubmed]
PHST- 2008/02/23 09:00 [medline]
PHST- 2007/11/09 09:00 [entrez]
AID - 10.1185/030079907X242773 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2007 Dec;23(12):3153-65. doi: 10.1185/030079907X242773.